+1 (855) PLE.XISION (753.9474) info@plexision.com
  • Dedicated To Individual Health
    Personalized medicine and drug development in organ transplantation and immunological disorders.
  • Pleximmune
    Predicts the risk of acute cellular rejection after liver or intestine transplantation in children.
  • Cell-Based Biomarkers
    Combined drug-biomarker development for immunological disorders.

FDA approves PleximmuneTM for personalized prediction of transplant rejection in children..

 
 

Plexision’s first patented product, the PleximmuneTM test, predicts the risk of acute cellular rejection after liver or intestine transplantation in children

Learn More +

Pleximmune - FAQs

PleximmuneTM is a blood test that helps your healthcare provider measure the risk of rejection after liver or intestine transplantation.
The PleximmuneTM test must be ordered by your healthcare provider The test requires a small blood sample, which can be obtained at the same time as the blood sample for routine transplant monitoring. The sample will be shipped to Plexision’s laboratory for analysis. Results will be sent to your healthcare provider within about 2 days of your blood being drawn. Your healthcare provider will help you understand what these results mean.
The PleximmuneTM measures the relative anti-donor activity in the recipient’s blood, compared with activity toward non-donor cells. This anti-donor activity is measured by the inflammatory response of a type of white blood cell called the T-cytotoxic memory lymphocyte. This inflammatory response tells your healthcare provider whether the risk of rejection is increased or decreased.

The PleximarkTM Tx test detects acute cellular rejection after renal transplantation.

Learn More +

PleximarkTMTx - FAQs

PleximarkTMTx is a blood test that helps your healthcare provider determine whether rejection is likely after renal transplantation.
The PleximarkTMTx test must be ordered by your healthcare provider The test requires a small blood sample, which can be obtained at the same time as the blood sample for routine transplant monitoring. The sample will be shipped to Plexision’s laboratory for analysis. Results will be sent to your healthcare provider within about 2 days of your blood being drawn. Your healthcare provider will help you understand what these results mean.
The PleximarkTM test determines whether the transplanted organ is eliciting an increased immune response from the transplant recipient. This type of immune response occurs during transplant rejection, and can be measured in a type of white blood cell called the T-cytotoxic memory lymphocyte. When present, this increased immune response tells your healthcare provider whether transplant rejection is likely or not.

Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post- marketing.

Learn More +

Immuno-Oncology is a rapidly growing area of tumor therapy that fights cancer               

  • by recruiting the patient’s immune system, or

  • with drugs that are based on immune mechanisms.

Learn More +